Greenwich LifeSciences focuses on developing GLSI-100, a HER2-positive breast cancer vaccine, recently granted FDA Fast Track designation. GLSI's Fast Track status offers regulatory advantages but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback